Understanding the evidence | Medicinal Cannabis NZ Guide

Medicinal cannabis in New Zealand is a regulated pharmaceutical route, not a general licence to use cannabis. Under the Misuse of Drugs Act 1975, access is legal only through a prescription from a medical practitioner, and items must meet Good Manufacturing Practice (GMP) standards and be approved by the Medicinal Cannabis Agency (MCA), which sits within Medsafe. The thing newcomers most often get wrong is that “legal medicinal cannabis” does not mean a patient can legally smoke raw plant material or buy unregulated goods; the legal option is a manufactured pharmaceutical, and the raw flower, while available, is prescribed and dispensed through a pharmacy, not a dispensary.

Understanding the evidence for medicinal cannabis

The evidence base for medicinal cannabis is still developing. In New Zealand, the Ministry of Health and the NZ Formulary rely on systematic reviews and peer-reviewed clinical guidance, not anecdote. For chronic pain, the strongest evidence supports a modest effect. For refractory epilepsy, the evidence is strongest for CBD-predominant preparations, particularly in specific paediatric syndromes. For anxiety and sleep, evidence is mixed; some patients benefit, but the data are not robust enough for first-line use. Cancer-related nausea and appetite loss have moderate evidence, but again not as first-line therapy. No systematic review supports medicinal cannabis as a first-line treatment for any condition, and the NZ Formulary does not endorse it as one.

How the New Zealand scheme works

New Zealand’s Medicinal Cannabis Scheme was established under the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 and came into effect on 1 April 2020. It is administered by the Medicinal Cannabis Agency inside Medsafe (New Zealand Ministry of Health, 2023). The scheme does not legalise cannabis generally; it legalises a route: a medical practitioner can prescribe an item that meets GMP standards and has been notified to the Ministry of Health. Qualifying items are listed on the New Zealand Medicinal Cannabis Register, and the prescriber writes a prescription through the normal NZ prescription system. Raw flower is available only as a prescribed pharmaceutical dispensed through a pharmacy, not as a loose herbal product.

The legal basis is the Misuse of Drugs Act 1975 and the Misuse of Drugs (Medicinal Cannabis) Regulations 2019. Under these, a medical practitioner can prescribe a medicinal cannabis preparation if they consider it clinically appropriate. The NZ Formulary lists the approved options and provides prescribing guidance for clinicians.

The scheme does not permit smoking raw plant material; the legal forms are manufactured pharmaceuticals (flower for vaporisation, oils, capsules, or powders). Flower must be prescribed and dispensed through a pharmacy. Home cultivation, possession without a prescription, and supply outside the regulated route are all prohibited. The Ministry of Health, via the Medicinal Cannabis Agency, oversees licensing and quality.

Key facts for patients

Access requires a prescription from a medical practitioner.
Every preparation must meet GMP standards and be approved by the Ministry of Health under the Medicinal Cannabis Scheme.
The scheme legalises access via prescription, not general use.
Raw plant material for smoking is not a medicinal item under the scheme, though some prescribed flower is available for vaporisation.
The Misuse of Drugs Act 1975 and Misuse of Drugs (Medicinal Cannabis) Regulations 2019 govern the scheme.
The Medicinal Cannabis Agency issues licences and enforces quality standards.

The evidence base by condition

Systematic reviews from the US National Academies (2017) found moderate evidence for chronic pain and for nausea from chemotherapy, but not for most other conditions. The NZ Formulary lists cannabis preparations for chronic pain, chemotherapy-induced nausea and vomiting, and refractory epilepsy in children and adults. For chronic pain, the strongest evidence supports a modest effect; do not expect elimination of pain, and track function and opioid-sparing as co-primary outcomes. For refractory epilepsy, the evidence is strongest for CBD-predominant preparations in specific paediatric syndromes such as Dravet syndrome and Lennox-Gastaut syndrome. For anxiety and sleep, evidence is mixed; some patients report benefit, but the data are not robust enough for first-line use, and adverse effects including sedation and tolerance must be weighed carefully. Cancer-related nausea and appetite loss have moderate evidence, positioned after standard antiemetics have failed. Across all conditions, the Ministry of Health and the NZ Formulary rely on systematic reviews and peer-reviewed clinical guidance, not anecdote.

How to choose among the options

Choosing among the many medicinal cannabis preparations in New Zealand requires a structured decision path. Work through these steps in order.

Step 1: Confirm the legal route

Under the Misuse of Drugs Act 1975, cannabis is a controlled drug, but the Medicinal Cannabis Scheme (established under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019) allows a medical practitioner to prescribe a manufactured cannabis preparation that meets GMP standards and is approved by the Ministry of Health. If an item is not on the scheme, it is not legal for medicinal use. Before you proceed, check the Medicinal Cannabis Agency’s product list. Book a consultation with a registered medical practitioner who is familiar with the scheme. Arrive with a summary of your diagnosis, previous treatments tried, and current medications. This step is about knowing the legal boundaries, not choosing a preparation yourself.

Step 2: Identify the condition and the outcome you are targeting

Cannabis is not a single drug; it is a family of preparations with different ratios of THC and CBD, different forms, and different onset and duration profiles. The evidence is condition-specific. Name the condition and the outcome you are targeting (for example, reduced nausea during chemotherapy cycles, fewer drop seizures per week, or improved sleep latency). Then ask your prescriber which preparation matches that condition-and-outcome pair. Skip any product marketed for a broad wellness claim without a specific, measurable target.

Step 3: Compare form, onset and duration

Once a preparation type is identified, compare the available forms. Oils and capsules have slower onset (30 to 90 minutes) and longer duration, making them more suitable for sustained symptom control. Vaporised flower has rapid onset (minutes) and shorter duration, which may suit breakthrough symptoms. Ask your prescriber to explain the pharmacokinetic profile of the specific product being considered, and confirm the starting dose and titration schedule in writing before leaving the consultation.

Step 4: Verify quality and pharmacy dispensing

Confirm that the prescribed item appears on the New Zealand Medicinal Cannabis Register. Take the prescription to a licensed pharmacy; medicinal cannabis flower is dispensed through a pharmacy, not a dispensary. At the pharmacy, ask to see the product’s GMP certification reference and check that the label matches the prescription exactly. Do not accept unlabelled or repackaged product.